Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 1/20 | 0.34 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.33 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17954258 | 0.85 | ITPR3 (0.33) | ITPR3ITPR1AKT1PLCG2PIK3R1 | |
| SCHEMBL17954259 | 0.81 | AKT1 (0.36) | ITPR3ITPR1AKT1PLCG2PIK3R1 | |
| SCHEMBL17954263 | 0.81 | AKT1 (0.36) | ITPR3ITPR1AKT1PLCG2PIK3R1 | |
| SCHEMBL17954260 | 0.81 | AKT1 (0.36) | ITPR3ITPR1AKT1PLCG2PIK3R1 | |
| SCHEMBL17954261 | 0.81 | AKT1 (0.36) | ITPR3ITPR1AKT1PLCG2PIK3R1 | |
| SCHEMBL17954294 | 0.73 | LPAR3 (0.35) | — | |
| SCHEMBL17954272 | 0.70 | AKT1 (0.33) | AKT1PLCG2PIK3R1AKT2PIK3CA | |
| SCHEMBL20215996 | 0.69 | AKT1 (0.30) | AKT1PLCG2PIK3R1AKT2PIK3CA | |
| SCHEMBL17954265 | 0.69 | — | — | |
| SCHEMBL17954224 | 0.68 | FBP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | ITPR3 815/4885ITPR1 648/4885AKT1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.